黑料网

Epithelial cells; Immune modulation; Therapeutic strategies; Cytokines; Chemokines; Antigen presentation; Immune cell crosstalk

Introduction

Epithelial cells, which line the surfaces of tissues and organs, serve as a physical barrier against pathogens and environmental stressors. Beyond their structural role, epithelial cells are also actively involved in regulating immune responses [1]. They produce cytokines, chemokines, and antimicrobial peptides, and can influence the behavior of immune cells, including dendritic cells, macrophages, and T lymphocytes. Given their pivotal role in immune regulation, epithelial cells have become an important target for therapeutic strategies aimed at modulating immune responses in diseases such as autoimmune disorders, chronic inflammatory conditions, and cancer. Understanding the mechanisms by which epithelial cells interact with the immune system is critical for developing therapies that can effectively target these cells to either suppress or enhance immune responses [2]. This article provides an overview of the molecular and cellular mechanisms underlying epithelial cell immune modulation, explores the various therapeutic strategies that are being developed to target epithelial cells in immune-related diseases, and discusses future directions in this rapidly evolving field.

Mechanisms of epithelial cell-mediated immune modulation

Epithelial cells play a critical role in the initiation and resolution of immune responses through the production of various cytokines and chemokines. These signaling molecules can attract immune cells to the site of infection or injury and influence their activation status. Upon exposure to pathogens or damage, epithelial cells can release pro-inflammatory cytokines such as interleukin-1 (IL-1), tumor necrosis factor-alpha (TNF-α), and interleukin-6 (IL-6), which activate innate immune responses [3]. These cytokines stimulate the recruitment and activation of neutrophils, macrophages, and dendritic cells, thus facilitating the initiation of adaptive immunity. In contrast, epithelial cells can also produce anti-inflammatory cytokines such as transforming growth factor-beta (TGF-β) and interleukin-10 (IL-10), which serve to limit excessive inflammation and promote tissue repair. These cytokines can suppress the activity of T helper 1 (Th1) and Th17 cells, promoting the development of regulatory T cells (Tregs), which are critical for maintaining immune homeostasis. Epithelial cells secrete chemokines, including CCL2, CCL5, and CXCL8, which mediate the trafficking of immune cells to sites of infection, injury, or inflammation [4]. Chemokine gradients guide immune cells to the affected areas, where they can exert their effector functions.

Antigen presentation and immune surveillance

Epithelial cells possess limited but essential antigen-presenting capabilities. While they lack the classic MHC class II expression found in professional antigen-presenting cells (APCs) like dendritic cells, certain epithelial cells, especially in mucosal tissues, can express MHC class I molecules and present antigens to CD8+ cytotoxic T cells.

MHC Class I and CD8+ T cell activation: In response to viral infection or stress, epithelial cells upregulate MHC class I molecules, enabling the presentation of endogenous antigens to CD8+ T cells [5]. This interaction can trigger cytotoxic responses against infected or transformed epithelial cells, playing a critical role in immune surveillance and tumor suppression.

MHC Class II and CD4+ T cell responses: In certain contexts, such as chronic inflammation or cancer, epithelial cells may also express MHC class II molecules, allowing them to interact with CD4+ T helper cells. This can result in either pro-inflammatory or regulatory immune responses, depending on the cytokine environment.

Pattern recognition receptors (PRRs) and immune signaling

Epithelial cells are equipped with a range of pattern recognition receptors (PRRs) that detect pathogen-associated molecular patterns (PAMPs) and damage-associated molecular patterns (DAMPs) [6]. These receptors, including Toll-like receptors (TLRs), NOD-like receptors (NLRs), and RIG-I-like receptors (RLRs), allow epithelial cells to sense microbial infections or tissue damage and initiate an immune response. TLRs on epithelial cells can recognize bacterial lipopolysaccharides (LPS), viral RNA, and other microbial products. Activation of TLRs leads to the production of pro-inflammatory cytokines and the recruitment of immune cells to the site of infection [7]. NLRs are involved in the detection of intracellular pathogens and cellular stress signals. The NLRP3 inflammasome, for instance, can be activated in epithelial cells in response to pathogen infection or cellular damage, leading to the activation of caspase-1 and the release of interleukin-1β (IL-1β), a potent pro-inflammatory cytokine. These receptors are primarily involved in the detection of viral RNA. Upon recognition of viral pathogens, RLRs trigger signaling pathways that activate type I interferons (IFNs), which play a critical role in antiviral immunity. Epithelial cells engage in direct interactions with various immune cells, such as dendritic cells, macrophages, and T lymphocytes, through cell surface receptors and secreted factors. These interactions shape the immune landscape and determine the outcome of inflammation or infection [8]. Epithelial cells in the skin, lungs, and gut can interact with dendritic cells, which are essential for antigen presentation and the initiation of adaptive immunity. These interactions are often mediated by cytokine signaling and direct cell-cell contact via surface receptors such as CD80/86 and ICAM-1. Epithelial cells can influence macrophage activation, polarization, and function through the release of cytokines and the expression of surface receptors such as E-cadherin, which modulate the macrophage phenotype from a pro-inflammatory M1 state to an anti-inflammatory M2 state. Epithelial cells interact with T lymphocytes through antigen presentation, co-stimulatory signaling, and cytokine release. In mucosal tissues, epithelial cells play a critical role in promoting the differentiation of T cells into specific subsets, such as Th17 cells in the gut or Tregs in the skin.

Therapeutic strategies targeting epithelial cells

Given their central role in immune regulation, epithelial cells represent an attractive target for therapeutic strategies aimed at modulating immune responses in a variety of diseases. Recent advancements in nanotechnology and drug delivery systems have allowed for the development of targeted therapies that can selectively deliver drugs to epithelial cells. Nanoparticles, liposomes, and dendrimers can be engineered to recognize specific receptors on epithelial cells, ensuring that the therapeutic agents reach their intended targets with minimal systemic exposure. These systems can encapsulate a variety of therapeutic agents, including small molecules, biologics, and RNA-based therapies, and deliver them directly to epithelial cells. For instance, nanoparticles targeting the epithelial cell surface markers (e.g., E-cadherin or integrins) can deliver anti-inflammatory or immunomodulatory drugs to treat autoimmune diseases or chronic inflammation. Liposomes and engineered viral vectors can be used to deliver gene therapies that modulate epithelial cell function. These vectors can introduce genetic material into epithelial cells to regulate immune signaling pathways, promote tissue repair, or suppress aberrant immune responses. Epithelial cells can be targeted by biologics or small molecules that modulate their immune functions. This includes therapies that either boost the immune response in cases of infection or cancer, or suppress inflammation in autoimmune diseases. Monoclonal antibodies targeting pro-inflammatory cytokines (e.g., TNF-α, IL-6) or cytokine receptors can help modulate the inflammatory responses initiated by epithelial cells. These therapies have shown efficacy in treating conditions like rheumatoid arthritis and inflammatory bowel disease (IBD). In cancer therapy, immune checkpoint inhibitors that target PD-1/PD-L1 or CTLA-4 can enhance the immune surveillance capabilities of epithelial cells. By blocking these inhibitory signals, the immune system is better able to recognize and eliminate cancer cells. Gene editing technologies such as CRISPR-Cas9 hold promise for selectively modifying epithelial cell functions. By targeting specific genes involved in immune signaling or epithelial cell differentiation, it may be possible to correct dysfunctional immune responses or promote tissue regeneration in diseases such as chronic obstructive pulmonary disease (COPD), IBD, or skin wounds. Gene silencing or activation: Gene therapies that either silence pro-inflammatory genes or activate protective immune genes in epithelial cells may provide a novel approach to treating inflammatory diseases or preventing infection. Stem cell therapies targeting epithelial cells are emerging as a potential treatment for tissue damage and immune modulation. Stem cells derived from various sources, including induced pluripotent stem cells (iPSCs) and mesenchymal stem cells (MSCs), can be used to regenerate damaged epithelial tissues and restore immune homeostasis.

Regenerative medicine: Stem cell-based therapies could be used to regenerate epithelial tissues in diseases like IBD or skin ulcers, restoring both structural integrity and immune function.

Future directions

As our understanding of epithelial cell biology and immune modulation deepens, personalized approaches to targeting epithelial cells will become increasingly feasible. By profiling an individual's epithelial cell immune signature, it may be possible to tailor therapeutic interventions that are more effective and have fewer side effects. The development of biomarkers to identify epithelial cell dysfunction or immune dysregulation will be crucial in advancing precision medicine. These biomarkers can help clinicians determine which patients are most likely to benefit from epithelial cell-targeted therapies. The continued advancement of drug delivery technologies, including advanced nanoparticles, exosome-based systems, and targeted biologics, will provide more precise and efficient ways to deliver therapeutics to epithelial cells. These platforms will be essential for improving the efficacy and reducing the toxicity of treatments. Future research should focus on uncovering the full range of immune-modulating roles of epithelial cells. A deeper understanding of how epithelial cells influence immune responses through both innate and adaptive mechanisms will open new avenues for therapeutic development in immune-related diseases.

Conclusion

Epithelial cells play a central role in immune modulation, and targeting these cells offers promising therapeutic potential for a variety of immune-related diseases. By leveraging advances in immunology, drug delivery systems, and gene therapies, new therapeutic strategies can be developed to selectively modulate epithelial cell functions. With continued research into the mechanisms of epithelial-immune cell interactions and the development of novel therapeutic tools, epithelial cell targeting is poised to become a cornerstone of immune modulation in clinical practice.

1. Pallone F, Monteleone G (1998) . Gut 43: 735-736.

, ,

2. Duchmann R, Kaiser I, Hermann E, Mayet W, Ewe K, et al. (1995) . Clin Exp Immunol 102: 448-455.

, ,

3. Strober W, Kelsall B, Fuss I, Marth T, Ludviksson B, et al. (1997) . Immunol Today 18: 61- 64.

听, ,

4. Aslam B, Khurshid M, Arshad MI, Muzammil S, Rasool M, et al. (2021) Frontiers in Cellular and Infection Microbiology 1153.

, ,

5. Doherty R, Madigan S, Warrington G, Ellis J (2019) Nutrients 11: 822.

, ,

6. Jagannath A, Taylor L, Wakaf Z, Vasudevan SR, Foster RG, et al. (2017) Hum Mol Genet 26: 128-138.

听, ,

7. Niessner M, Volk BA (1995) . Clin Exp Immunol 101: 428-435.

, ,

8. Matsuura T, West GA, Youngman KR, Klein JS, Fiocchi C, et al. (1993) . Gastroenterology 104: 448-458.

, ,